AR018179A1 - Un proceso para la preparacion de preparaciones farmaceuticas que comprenden carvedilol o 4-[2-hidroxi-3-[ 4-fenoximetil)piperidino]-propoxi]-indol - Google Patents

Un proceso para la preparacion de preparaciones farmaceuticas que comprenden carvedilol o 4-[2-hidroxi-3-[ 4-fenoximetil)piperidino]-propoxi]-indol

Info

Publication number
AR018179A1
AR018179A1 ARP990101574A ARP990101574A AR018179A1 AR 018179 A1 AR018179 A1 AR 018179A1 AR P990101574 A ARP990101574 A AR P990101574A AR P990101574 A ARP990101574 A AR P990101574A AR 018179 A1 AR018179 A1 AR 018179A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical preparations
preparation
phenoximethyl
propoxi
indol
Prior art date
Application number
ARP990101574A
Other languages
English (en)
Original Assignee
Roche Diagnostics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1998116036 external-priority patent/DE19816036A1/de
Priority claimed from EP98112241A external-priority patent/EP0968714A1/de
Application filed by Roche Diagnostics Gmbh filed Critical Roche Diagnostics Gmbh
Publication of AR018179A1 publication Critical patent/AR018179A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se refiere a un proceso para la preparacion de preparaciones farmacéuticas de rápida disolucion de sustancias activas de solubilidad dificultosa, porejemplo carvedilol, con una velocidad de disolucion de al menos el 70% después de 30 minutos, que comprende preparar una suspension acuosa de lasustancia activa y uno o más adyuvantes solubles en agua, y luego procesar la suspension acuosa resultante, con remocion del agua, por medio de losmétodos conocidos per se, para formar preparaciones farmacéuticas solidas. También se refiere a preparaciones farmacéuticas de rápida disolucion de sustanciasactivas que tienen una velocidad de disolucion de al menos el 70% después de 30 minutos, preparada de acuerdo con el proceso de la invencion y el usodedicho proceso para la preparacion de preparaciones farmacéuticas de rápida disolucion de una sustancia activa con solubilidad dificultosaque tiene una velocidad de disolucion de al menos el 70% después de 30 minutos.
ARP990101574A 1998-04-09 1999-04-07 Un proceso para la preparacion de preparaciones farmaceuticas que comprenden carvedilol o 4-[2-hidroxi-3-[ 4-fenoximetil)piperidino]-propoxi]-indol AR018179A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE1998116036 DE19816036A1 (de) 1998-04-09 1998-04-09 Verfahren zur Herstellung schnellauflösender pharmazeutischer Zubereitungen von schwerlöslichen Wirkstoffen
EP98112241A EP0968714A1 (de) 1998-07-02 1998-07-02 Verfahren zur Herstellung schnellauflösender pharmazeutischer Zubereitungen von schwerlöslichen Wirkstoffen

Publications (1)

Publication Number Publication Date
AR018179A1 true AR018179A1 (es) 2001-10-31

Family

ID=26045401

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990101574A AR018179A1 (es) 1998-04-09 1999-04-07 Un proceso para la preparacion de preparaciones farmaceuticas que comprenden carvedilol o 4-[2-hidroxi-3-[ 4-fenoximetil)piperidino]-propoxi]-indol

Country Status (12)

Country Link
EP (1) EP1069896B1 (es)
JP (2) JP3947654B2 (es)
KR (1) KR100520589B1 (es)
CN (1) CN1151788C (es)
AR (1) AR018179A1 (es)
AT (1) ATE246502T1 (es)
AU (1) AU3522399A (es)
CA (1) CA2326840C (es)
DE (1) DE69910188T2 (es)
DK (1) DK1069896T3 (es)
ES (1) ES2204121T3 (es)
WO (1) WO1999052526A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
US6682759B2 (en) * 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
CA2492084A1 (en) 2002-06-27 2004-01-08 Sb Pharmco Puerto Rico Inc. Carvedilol hydobromide
KR101468827B1 (ko) 2002-06-27 2014-12-03 스미스클라인 비이참 (코르크) 리미티드 카베딜롤 인산염 및(또는) 그의 용매화물, 상응하는 조성물, 및(또는) 치료 방법
EP1686986A4 (en) 2003-11-25 2009-05-27 Sb Pharmco Inc CARVEDILOL SALTS, CORRESPONDING COMPOSITIONS, METHODS OF ADMINISTRATION AND / OR TREATMENT
US20050175695A1 (en) 2003-11-25 2005-08-11 Catherine Castan Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
US8367112B2 (en) 2006-02-28 2013-02-05 Alkermes Pharma Ireland Limited Nanoparticulate carverdilol formulations
ATE539769T1 (de) 2008-03-04 2012-01-15 Lupin Ltd Stabile pharmazeutische zusammensetzungen mit carvedilol
TWI415604B (zh) * 2009-09-29 2013-11-21 Tsh Biopharm Corp Ltd 調控釋放卡菲蒂羅劑型
MX2012010555A (es) * 2010-03-29 2012-10-05 Firmenich & Cie Ingrediente activo cristalino secado por rociado.
CN104528744A (zh) * 2015-01-15 2015-04-22 中国药科大学 一种扩孔介孔二氧化硅的简单制备及其促溶应用
KR102158339B1 (ko) 2016-02-05 2020-09-21 삼진제약주식회사 인습성이 개선된 카르베딜롤 속방성 제제

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2815926A1 (de) * 1978-04-13 1979-10-18 Boehringer Mannheim Gmbh Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
JPH0249720A (ja) * 1988-05-18 1990-02-20 Mitsubishi Kasei Corp 難溶性薬剤組成物
JPH0776516A (ja) * 1993-09-06 1995-03-20 Toyobo Co Ltd 難溶性薬物含有製剤の製造方法
JPH107558A (ja) * 1996-06-19 1998-01-13 Eisai Co Ltd 溶解性改善製剤
DE19637082A1 (de) * 1996-09-12 1998-03-19 Boehringer Mannheim Gmbh Schnellzerfallende Pellets

Also Published As

Publication number Publication date
JP3947654B2 (ja) 2007-07-25
KR100520589B1 (ko) 2005-10-10
WO1999052526A1 (en) 1999-10-21
DE69910188D1 (de) 2003-09-11
ATE246502T1 (de) 2003-08-15
JP2007145856A (ja) 2007-06-14
KR20010042574A (ko) 2001-05-25
JP2002511413A (ja) 2002-04-16
CA2326840C (en) 2007-08-07
CN1151788C (zh) 2004-06-02
EP1069896B1 (en) 2003-08-06
ES2204121T3 (es) 2004-04-16
DE69910188T2 (de) 2004-06-17
CN1295472A (zh) 2001-05-16
AU3522399A (en) 1999-11-01
DK1069896T3 (da) 2003-11-17
EP1069896A1 (en) 2001-01-24
CA2326840A1 (en) 1999-10-21

Similar Documents

Publication Publication Date Title
AR018179A1 (es) Un proceso para la preparacion de preparaciones farmaceuticas que comprenden carvedilol o 4-[2-hidroxi-3-[ 4-fenoximetil)piperidino]-propoxi]-indol
ES2190075T3 (es) Formulaciones farmaceuticas solidas que contienen una mezcla fisica de sulfoalquil-eter-ciclodextrina y un agente terapeutico.
ATE333265T1 (de) Oral anzuwendende schnell zerfallende feste darreichungsformen
CY1110906T1 (el) Φαρμακευτικη συνθεση για ρινικη χορηγηση φεντανυλης
ECSP044974A (es) Formulación de suspensión oral estabilizada
ATE177647T1 (de) Cyclodextrin-komplexation
FR2627696B1 (fr) Nouvelle forme galenique du fenofibrate
GT199900069A (es) Preparaciones farmaceuticas estabilizadas de gabapentina y proceso para prepararla.
UY27273A1 (es) Solución oral de arilpiprazol
CY1107384T1 (el) Ταχεως διασπειρομενες μορφες δοσομετρησεως ανευ ζελατινης
CY1105771T1 (el) Φαρμακευτικες συνθεσεις εφαρμογης στον βλεννογονο
PA8575701A1 (es) Preparaciones acidas de insulina con estabilidad mejorada
GT199800113A (es) Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion.
CO5700832A2 (es) Suspensiones acuosas de ciclesonide para nebulizacion
ECSP066313A (es) Derivados de la piridazina y su uso como agentes terapéuticos
ECSP066315A (es) Derivados de la piridazina y su uso como agentes terapéuticos
ATE397602T1 (de) 9-(piperazinylalkyl)carbazole als bax-modulatoren
NO20011721D0 (no) N-aralkylaminotetraliner som ligander for neuropeptid Y Y5 reseptor
ECSP066312A (es) Derivados piridilo y su uso como agentes terapéuticos
NO20021859D0 (no) Nye digosakkarider, deres fremstilling samt farmasöytiske preparater
AR018197A1 (es) Compuestos de piperidina, un procedimiento para su preparacion, una composicion y uso del mismo para la preparacion de un medicamento
CY1105515T1 (el) Μεθοδος παρασκευης στερεων διασπορων
YU2200A (sh) Termodinamički stabilna modifikacija 1-(4-karbazoliloksi)-3-/2-(2-metoksifenoksi)etilamino/-2-propanola, postupak za njeno dobijanje i farmaceutske smeše koje je sadrže
IT1314185B1 (it) Composizione farmaceutica per somministrazione di sostanze attivescarsamente solubili in mezzi acquosi
TR200100895T2 (tr) Heterosiklik ikameli propanolamin türevleri, üretimi, ilaçları,kullanımı

Legal Events

Date Code Title Description
FA Abandonment or withdrawal